News

This approval is based on results from a multicentre, randomised, double-blind, placebo-controlled Phase III trial. The study’s co-primary endpoints were achieving a minimum of a 75% improvement in

EN001, a clinical-stage mesenchymal stem cell therapy in ENCell’s pipeline, is developed using mesenchymal stem cells sourced from the early culture stage. Preclinical studies are said to have

A rapidly advancing class of therapeutic agents, ADCs target and selectively eliminate tumour cells while sparing healthy ones. Dubbed Mobius ADC Reactor, the offering is engineered to meet

Under the terms of the agreement, KM Biologics will carry out the development, manufacturing, and commercialisation of Osivax’s vaccine. KM Biologics will make an upfront payment to Osivax

RA Capital Management spearheaded the financing round with contributions from current investors namely Insight Partners, NVentures and Gaingels. New participants in this funding round included Catalio Capital Management,

This recommendation will aid in the potential authorisation of the vaccine for use in individuals aged six months and older to prevent Covid-19 in the upcoming 2024-2025 autumn/winter

The first facility is breaking ground at the Novartis site in Indianapolis, dedicated to the production of radioisotopes essential for RLT manufacturing. This expansion is set to bolster

With the MHRA approval, the updated vaccine will be included in the National Health Service (NHS) autumn vaccination programme. The company noted that the vaccine will be given

SKG1108 is a one-time intravitreally delivered therapy, which uses a recombinant adeno-associated virus (rAAV) vector to target the condition. It employs the AAV.0106 capsid to deliver a single-stranded